The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B

Journal of Gastroenterology

Volumn 39, Issue 3, 2004, Pages 260-267

  Shindo, Michiko ^a   Hamada, Kazushige ^b   Nishioji, Kenichi ^a   Muramatsu, Akira ^a   Oda, Yoko ^a   Okuno, Tadao ^a  

^a Akashi Municipal Hospital   (Japan)

^b KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Chronic hepatitis B; Interferon; Lamivudine; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; DRUG EFFICACY; FEMALE; GENE MUTATION; HEALTH STATUS; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN MOTIF; RETROSPECTIVE STUDY; SCORING SYSTEM; SEROCONVERSION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTIC ACID; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; MALE; METHIONINE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TYROSINE;

EID: 1942504426     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1293-6     Document Type: Article

References (34)

1. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55.
2. Beasley RP, Hwang LW, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981;II:1129-33.
3. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic hepatitis. N Engl J Med 1997;336:347-56.
4. Wong DKH, Cheung AM, O'Rourke K, Nayler CD, Detxy AS, Heathcote EJ. Effect of alpha-interferon treatment in patients with chronic hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
5. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg positive patients with chronic active hepatitis after alpha-interferon therapy. N Engl J Med 1996;334:1422-7.
6. Lau DT-Y, Everhault J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
7. Dienstag JL, Perrillo RP, Shiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
8. Nevens F, Main J, Honkoop P, Tyrrel DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a 6-month randomized dose-ranging study. Gastroenterology 1997;113: 1258-63.
9. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A 1-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
10. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
11. Hookoop P, de Man RA, Heitjitink RA, Schlam SW. Hepatitis B reactivation after lamivudine. Lancet 1995;346:1156-7.
12. Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
13. Tripples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in the HBV RNA dependent DNA polymerase confers resistance of lamivudine in vivo. Hepatology 1996;24:711-3.
14. Yeh C-T, Chien R-N, Chu A-M, Liaw Y-F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
15. Lau DT-Y, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
16. Yuen M-F, Sablon E, Hui C-K, Yuan H-J, Decraemer H, Lai C-L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91.
17. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)Sdd(3TC) resistance. Biochem Pharmacol 1998;55:1567-72.
18. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382-5.
19. Saab S, Kim M, Wright TL, Han SHB, Martin P, Busttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2001;119:1382-4.
20. Perrillo RP, Lai C-L, Liaw Y-F, Dienstag J-L, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
21. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-25.
22. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
23. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3.
24. Hope AH, Craig PI, Grierson JM. Interferon alfa for chronic active hepatitis B. Long-term follow-up of 62 patients: outcomes and predictors of response. Med J Aust 1995;162:8-11.
25. Lok ASF, Wu P-C, Lai C-L, Leung EKY, Wong LSK, Ma OC. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
26. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyamura Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999;80:97-112.
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
28. Sheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
29. Bedossa P, Poynard T, the METAVIR Cooperative Group. Inter-and intra-observer variations in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:15-20.
30. Bedossa P, Poynard T, the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93.
31. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J, et al. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000;20:47-55.
32. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32: 803-6.
33. Schiff E, Cianciara J, Karayalcin S, Kowdley K, Woesner M, McMullen S, et al. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (abstract). J Hepatol 2000;32:(Suppl 2);99.
34. Carman W, Thomas H, Domingo E. Viral genetic variation: hepatitis B virus as a clinical example. Lancet 1993;341:349-53.